首页> 美国卫生研究院文献>Journal of Clinical Oncology >Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

【2h】

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

机译：氟达拉滨和利妥昔单抗诱导治疗后未经皮下注射Alemtuzumab的巩固治疗：先前未治疗的慢性淋巴细胞白血病：CALGB 10101的最终分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia.

机译：目的确定在先前未治疗的有症状的慢性淋巴细胞性白血病患者中，诱导化疗后，阿仑单抗巩固治疗是否能改善应答率和无进展生存期（PFS）。

著录项

期刊名称 Journal of Clinical Oncology
作者
Thomas S. Lin; Kathleen A. Donohue; John C. Byrd; Margaret S. Lucas; Eva E. Hoke; Elizabeth M. Bengtson; Kanti R. Rai; James N. Atkins; Brian K. Link; Richard A. Larson;
展开▼
作者单位

展开▼
年(卷),期 -1(28),29
年度 -1
页码 4500–4506
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-21 10:53:19

相似文献

外文文献
中文文献
专利

1. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. [J] . Lin TS, Donohue KA, Byrd JC, Journal of Clinical Oncology . 2010,第29期

机译：在氟达拉滨和利妥昔单抗诱导治疗后，皮下注射阿仑单抗的巩固疗法用于先前未治疗的慢性淋巴细胞性白血病：CALGB 10101的最终分析。
2. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: Subgroup analysis from CALGB 19901 and CALGB 10101 [J] . JonesJ.A., RuppertA.S., ZhaoW., Leukemia and lymphoma . 2013,第12期

机译：具有高风险基因组特征的慢性淋巴细胞性白血病患者在连续进行的Alemtuzumab合并治疗的癌症和白血病B组试验中结果较差：来自CALGB 19901和CALGB 10101的亚组分析
3. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. [J] . Byrd JC, Byrd JC, Peterson BL Leukemia and lymphoma . 2009,第10期

机译：氟达拉滨随后阿仑单抗巩固治疗之前未治疗的慢性淋巴细胞性白血病：癌症和白血病B组研究19901的最终报告。
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGB trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101 [O] . Jeffrey A. Jones, Amy S. Ruppert, Weiqiang Zhao, -1

机译：具有高风险基因组特征的慢性淋巴细胞性白血病患者在连续的CALGB试验与alemtuzumab合并治疗中的结局较差：来自CALGB 19901和CALGB 10101的亚组分析
7. Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101 [O] . Lin, Thomas S., Donohue, Kathleen A., Byrd, John C., 2010

机译：氟达拉滨和利妥昔单抗诱导治疗后未经皮下注射Alemtuzumab的巩固治疗：先前未治疗的慢性淋巴细胞白血病：CALGB 10101的最终分析

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

摘要

著录项

相似文献

相关主题

期刊订阅